A Phase 2 Multicenter Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia
Brief description of study
Please see section 1 of protocol
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Frontotemporal Dementia
-
Age: - 99 Years
-
Gender: All
Updated on
23 Sep 2022.
Study ID: 833421
